Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12491697 | 1.00 | F2 (0.50) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL2176369 | 1.00 | F2 (0.50) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL14647983 | 1.00 | F2 (0.50) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL13571817 | 1.00 | F2 (0.50) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL14723789 | 0.93 | KCNH2 (0.55) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL13571431 | 0.89 | ALDH1A1 (0.50) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL12487606 | 0.89 | ALDH1A1 (0.46) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL2194014 | 0.89 | ALDH1A1 (0.46) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL2194019 | 0.89 | ALDH1A1 (0.46) | F2CYP2C9CYP2C19EP300CREBBP | |
| SCHEMBL845452 | 0.85 | F2 (0.52) | F2CYP2C9CYP2C19EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | claimed |
| EP-2519506-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-11-07 | — | — | EP | claimed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | claimed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | claimed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | F2 3824/4885CYP2C9 2875/4885CYP2C19 3727/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | F2 3824/4885CYP2C9 2875/4885CYP2C19 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.